Contraindications for Percutaneous Coronary Intervention (PCI) in Coronary Artery Disease

Absolute Contraindications

The American College of Cardiology and American Heart Association recommend that PCI should not be performed in stable patients without objective evidence of ischemia, those with insignificant stenosis (<50%), patients with only small areas of myocardium at risk, or when lesion morphology suggests low likelihood of success 1, 2
PCI provides no benefit when ischemia cannot be documented, regardless of angiographic appearance, in patients with no objective evidence of ischemia on noninvasive testing 1, 2, 3
Insignificant disease (<50% coronary stenosis) does not warrant intervention, as these lesions do not cause significant ischemia 1, 2, 4
The procedural risk outweighs any potential benefit in patients with only a small area of viable myocardium at risk 1, 2, 4, 3
Lesions with low likelihood of successful dilatation, such as those with unfavorable morphology, predict poor outcomes 1, 3
High risk of procedure-related morbidity or mortality, such as in patients with significant comorbidities, is a contraindication for PCI 1, 2, 4
Significant left main disease (>50% stenosis) when patient is a CABG candidate, as CABG provides superior outcomes in this population 1, 2, 4, 3
Mild symptoms unlikely due to myocardial ischemia, as PCI will not relieve non-ischemic chest pain 1, 3

Totally occluded infarct artery >24 hours after STEMI in asymptomatic, hemodynamically stable patients with 1- or 2-vessel disease and no severe ischemia, as multiple trials demonstrate no benefit beyond optimal medical therapy 5, 6, 7, 8
Noninfarct artery PCI at time of primary PCI in hemodynamically stable patients, as this approach causes harm and worsens clinical outcomes unless the patient is in cardiogenic shock 5, 6, 7, 8
Routine prophylactic coronary revascularization in stable CAD patients before noncardiac surgery, as this strategy does not improve perioperative outcomes 6, 7, 8

Balloon angioplasty or bare metal stents should be used instead of drug-eluting stents in patients with high bleeding risk, those who cannot comply with 12 months of dual antiplatelet therapy, or those with anticipated invasive or surgical procedures within 12 months that will require DAPT interruption 8
Extreme caution is warranted in patients with prior GI bleeding, and if PCI is necessary, shorten DAPT duration to 1-3 months with drug-eluting stents, use clopidogrel rather than ticagrelor or prasugrel, and prescribe a proton pump inhibitor 9

Hospitals unable to achieve first medical contact-to-device time of ≤120 minutes for transfer patients should use fibrinolytic therapy instead of PCI, as delayed PCI is associated with worse outcomes 5
Elective noncardiac surgery must not be performed within 4-6 weeks after balloon angioplasty or bare metal stent, or within 12 months after drug-eluting stent implantation, due to the risk of stent thrombosis 6, 7, 8, 9

The prohibition against PCI in stable patients without objective ischemia is supported by multiple randomized trials showing no mortality or MI reduction compared to optimal medical therapy alone 1, 2, 3
The evidence is particularly strong against late opening of occluded infarct arteries, with trials showing no benefit in preserving LV function or preventing cardiovascular events when performed 1-28 days post-MI in stable patients 5

The ACC/AHA guidelines define a coronary lesion as significant only when it is ≥50 % diameter reduction in the left main artery or ≥70 % in non‑left‑main vessels; lesions below these thresholds are considered insignificant and do not merit revascularization. 10

PCI is a Class III (Harm) recommendation for patients with stable ischemic heart disease when coronary stenoses are anatomically or functionally non‑significant (i.e., <70 % diameter stenosis in non‑left‑main arteries or fractional flow reserve > 0.80). 10

In stable patients with angiographic stenosis <50 % and TIMI grade 3 flow, the disease is hemodynamically insignificant; therefore, PCI should be avoided because procedural risks outweigh any potential benefit. 11, 12

For intermediate stenoses (50–70 %), functional testing (e.g., fractional flow reserve or stress imaging) is required; PCI is considered only if these tests demonstrate inducible ischemia. 10

For patients with insignificant stenosis and TIMI 3 flow, optimal medical therapy is the preferred strategy and includes:

In STEMI, the therapeutic goal is to restore TIMI 3 flow in an occluded artery; however, for arteries that already exhibit TIMI 3 flow, late PCI (>24 h) provides no benefit and carries a Class III recommendation against it. 16, 14, 15